Gossamer Bio, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $17.0M | $13.8M | $13.3M | $11.5M | $9.9M | $9.4M | $9.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $8.9M | $18.7M | $10.9M | $9.4M | $8.7M | $8.7M | $9.4M | $8.5M |
| Operating Income | $-26.1M | $-44.9M | $-46.0M | $-49.1M | $-38.8M | $-36.8M | $-36.1M | $-33.9M |
| Operating Margin | -282.2% | -264.6% | -333.6% | -369.4% | -337.4% | -372.2% | -385.2% | -357.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | $-48.2M | $-38.3M | — | — | $-31.9M |
| Income Tax Expense | — | — | — | $0 | $0 | — | — | $-1.1M |
| Net Income | $16.9M | $-46.7M | $-47.2M | $-48.2M | $-38.3M | $-36.6M | $-33.0M | $-30.8M |
| Net Margin | 182.9% | -275.2% | -342.3% | -362.7% | -333.1% | -370.5% | -352.2% | -324.9% |
| EPS (Basic) | $0.05 | $-0.20 | $-0.21 | $-0.21 | $-0.17 | $-0.16 | $-0.14 | $-0.14 |
| EPS (Diluted) | $-0.08 | $-0.20 | $-0.21 | $-0.21 | $-0.17 | $-0.16 | $-0.14 | $-0.14 |
| Shares Outstanding (Basic) | 320.0M | 234.1M | 228.5M | 228.0M | 227.3M | 226.8M | 226.2M | 226.3M |
| Shares Outstanding (Diluted) | 328.8M | 234.1M | 228.5M | 228.0M | 227.3M | 226.8M | 226.2M | 226.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |